2016
DOI: 10.1007/s00439-016-1686-2
|View full text |Cite
|
Sign up to set email alerts
|

Genome editing and the next generation of antiviral therapy

Abstract: Engineered endonucleases such as homing endonucleases (HEs), zinc finger nucleases (ZFNs), Tal-effector nucleases (TALENS) and the RNA-guided engineered nucleases (RGENs or CRISPR/Cas9) can target specific DNA sequences for cleavage, and are proving to be valuable tools for gene editing. Recently engineered endonucleases have shown great promise as therapeutics for the treatment of genetic disease and infectious pathogens. In this review, we discuss recent efforts to use the HE, ZFN, TALEN and CRISPR/Cas9 gene… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
32
0
1

Year Published

2016
2016
2020
2020

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 42 publications
(33 citation statements)
references
References 104 publications
0
32
0
1
Order By: Relevance
“…Thus far, the history of oligonucleotide therapeutics shows that success hinges on proactive pursuit of robust evidence closely aligned with the so-called 5 pillars of drug discovery (Cook et al, 2014). The commercial demise of fomivirsen (Krieg, 2011), the safety ambivalence of mipomersen (Panta, Dahal, & Kunwar, 2015), the questionable efficacy of the splicing modulators drisapersen (Hodgkinson et al, 2016) and eteplirsen (Miceli & Nelson, 2016), and the phase II/III failures or commercial abandonment of synthetic and virus-expressed siRNA drugs (Quark Pharmaceuticals and Benitec BioPharma, respectively) has turned the focus onto technological alternatives such as gene-editing (Stone, Niyonzima, & Jerome, 2016) and in vitro transcribed RNA (Devoldere, Dewitte, De Smedt, & Remaut, 2016).…”
Section: Concluding Remarks and Future Challengesmentioning
confidence: 99%
“…Thus far, the history of oligonucleotide therapeutics shows that success hinges on proactive pursuit of robust evidence closely aligned with the so-called 5 pillars of drug discovery (Cook et al, 2014). The commercial demise of fomivirsen (Krieg, 2011), the safety ambivalence of mipomersen (Panta, Dahal, & Kunwar, 2015), the questionable efficacy of the splicing modulators drisapersen (Hodgkinson et al, 2016) and eteplirsen (Miceli & Nelson, 2016), and the phase II/III failures or commercial abandonment of synthetic and virus-expressed siRNA drugs (Quark Pharmaceuticals and Benitec BioPharma, respectively) has turned the focus onto technological alternatives such as gene-editing (Stone, Niyonzima, & Jerome, 2016) and in vitro transcribed RNA (Devoldere, Dewitte, De Smedt, & Remaut, 2016).…”
Section: Concluding Remarks and Future Challengesmentioning
confidence: 99%
“…To the extent that viral latency is evaluated only in dissected dorsal root ganglia, it is possible that important sites of latency could be missed. For example, the emergence of the fairly diffuse autonomic ganglia as an important reservoir of reactivating virus suggests that gene therapy directed only at the DRG is unlikely to be successful in eradicating all latent or reactivating virus (30). Similarly, antivirals designed to specifically target reactivation mechanisms in sensory neurons may not be effective in autonomic neurons.…”
Section: Discussionmentioning
confidence: 99%
“…Each of these technologies specifically recognize and locate a target sequence with homologous binding specific protein domains or the guide RNA (gRNA) and catalyze a DNA double stranded break by attached restriction enzyme and reviewed extensively in recent past (167). Because of the precision of programmable nucleases these technologies are proposed as a powerful antiviral therapy for persistent viral infections (168,169). Proof-of-concept studies have been performed to treat multiple disorders, including in vivo experiments in mammals and even early phase human trials (NCT01455389, NCT00595088, and NCT01118052).…”
Section: Hpv Genome Targeting Approachesmentioning
confidence: 99%